肝细胞癌患者射频消融治疗后血清的蛋白质组学分析
Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment.
作者信息
Kawakami Takayuki, Hoshida Yujin, Kanai Fumihiko, Tanaka Yasuo, Tateishi Keisuke, Ikenoue Tsuneo, Obi Shuntaro, Sato Shinpei, Teratani Takuma, Shiina Shuichiro, Kawabe Takao, Suzuki Takamasa, Hatano Naoya, Taniguchi Hisaaki, Omata Masao
机构信息
Department of Gastroenterology, Graduate School of Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
出版信息
Proteomics. 2005 Nov;5(16):4287-95. doi: 10.1002/pmic.200401287.
Comparative proteomic analysis was used to search for characteristic alterations in the sera of hepatocellular carcinoma (HCC) patients who had undergone curative radiofrequency ablation treatment. Serum samples collected from eight patients before and after treatment were subjected to 2-DE. Eighty-eight protein spots differentially expressed with the treatment were selected by clustering analysis, and the proteins were identified by MS based on MALDI-TOF/TOF analysis and public database searches. The statistical analysis suggested that four proteins decreased after treatment (pro-apolipoprotein, alpha2-HS glycoprotein, apolipoprotein A-IV precursor, and PRO1708/PRO2044, which is the carboxy terminal fragment of albumin) and that seven proteins were increased after treatment, including leucine-rich alpha2-glycoprotein and alpha1-antitrypsin. These data facilitate the identification of differentially expressed proteins that are involved in HCC carcinogenesis and provide candidate biomarkers for the development of diagnostic and therapeutic tools.
采用比较蛋白质组学分析方法，寻找接受根治性射频消融治疗的肝细胞癌（HCC）患者血清中的特征性变化。收集8例患者治疗前后的血清样本，进行双向电泳（2-DE）。通过聚类分析选择88个与治疗相关的差异表达蛋白点，并基于基质辅助激光解吸电离飞行时间/串联飞行时间（MALDI-TOF/TOF）分析和公共数据库搜索，用质谱法鉴定这些蛋白。统计分析表明，治疗后4种蛋白减少（前载脂蛋白、α2-HS糖蛋白、载脂蛋白A-IV前体以及PRO1708/PRO2044，后者是白蛋白的羧基末端片段），7种蛋白增加，包括富含亮氨酸的α2-糖蛋白和α1-抗胰蛋白酶。这些数据有助于鉴定参与HCC致癌过程的差异表达蛋白，并为开发诊断和治疗工具提供候选生物标志物。
Zotero 插件